Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

103,810 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial.
Bril V, Hadden RDM, Brannagan TH 3rd, Bar M, Chroni E, Rejdak K, Rivero A, Andersen H, Latov N, Levine T, Pasnoor M, Sacconi S, Souayah N, Anderson-Smits C, Duff K, Greco E, Hasan S, Li Z, Yel L, Ay H. Bril V, et al. Among authors: li z. J Peripher Nerv Syst. 2023 Sep;28(3):436-449. doi: 10.1111/jns.12573. Epub 2023 Jul 6. J Peripher Nerv Syst. 2023. PMID: 37314318 Clinical Trial.
Corrigendum to "Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies" [Int. Immunopharmacol. 113(Part A) (2022) 109331].
Li Z, Follman K, Freshwater E, Engler F, Yel L. Li Z, et al. Int Immunopharmacol. 2023 Jan;114:109555. doi: 10.1016/j.intimp.2022.109555. Epub 2022 Dec 15. Int Immunopharmacol. 2023. PMID: 36527876 No abstract available.
103,810 results
You have reached the last available page of results. Please see the User Guide for more information.